Correlation Between Vaxcyte and Monte Rosa
Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxcyte and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Vaxcyte and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Monte Rosa.
Diversification Opportunities for Vaxcyte and Monte Rosa
0.27 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Vaxcyte and Monte is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Vaxcyte i.e., Vaxcyte and Monte Rosa go up and down completely randomly.
Pair Corralation between Vaxcyte and Monte Rosa
Given the investment horizon of 90 days Vaxcyte is expected to generate 0.68 times more return on investment than Monte Rosa. However, Vaxcyte is 1.47 times less risky than Monte Rosa. It trades about -0.06 of its potential returns per unit of risk. Monte Rosa Therapeutics is currently generating about -0.08 per unit of risk. If you would invest 8,199 in Vaxcyte on December 29, 2024 and sell it today you would lose (1,122) from holding Vaxcyte or give up 13.68% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Vaxcyte vs. Monte Rosa Therapeutics
Performance |
Timeline |
Vaxcyte |
Monte Rosa Therapeutics |
Vaxcyte and Monte Rosa Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Vaxcyte and Monte Rosa
The main advantage of trading using opposite Vaxcyte and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.Vaxcyte vs. Day One Biopharmaceuticals | Vaxcyte vs. Mirum Pharmaceuticals | Vaxcyte vs. Rocket Pharmaceuticals | Vaxcyte vs. Avidity Biosciences |
Monte Rosa vs. Nkarta Inc | Monte Rosa vs. Lyell Immunopharma | Monte Rosa vs. Generation Bio Co | Monte Rosa vs. Sana Biotechnology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data |